Clinical Trial Update: Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ

View source ↗

Summary

Non-interventional post-authorisation study assessing immunogenicity, safety, and efficacy of NUWIQ in Hemophilia A has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Nuwiq (recombinant factor VIII concentrate)

Snippet

Sponsor: Octapharma | Conditions: Hemophilia A | Status: COMPLETED | Results posted: 2021-09-28